申请人:Glaxo Group Limited
公开号:US20170119750A1
公开(公告)日:2017-05-04
Compounds of formula (I):
wherein;
R
1
is hydrogen or C
1-6
alkyl;
R
2
is hydrogen, C
1-6
alkyl, perhalomethylC
0-5
alkyl-O—, or C
1-6
alkoxy;
R
3
is hydrogen, C
1-6
alkyl, or C
1-6
alkoxyC
1-6
alkyl;
R
4
is hydrogen, C
1-6
alkyl, perhalomethylC
1-6
alkyl; or unsubstituted C
3-6
cycloalkylC
1-6
alkyl;
A is C—R
5
or N;
B is C—R
6
or N;
D is C—R
7
or N;
with the proviso that at least one of A, B, and D, is N;
R
5
is hydrogen or C
1-6
alkyl;
R
6
is hydrogen or C
1-6
alkyl;
R
7
is hydrogen, C
1-6
alkyl, C
1-6
alkoxy, or hydroxy;
R
8
is hydrogen or C
1-6
alkyl, with the proviso that one of R
4
and R
8
is hydrogen;
R
9
is hydrogen or hydroxy;
R
10
is hydrogen or C
1-6
alkyl;
and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.